TP53 and hematologic disorder: In summary, more studies with molecules targeting mutant p53 (APR-246 being the only one, which has been employed in hematologic malignancies) are needed, as it is not yet clear, which of the nearly 1,500 different missense mutations they are able to target (48) but first results are encouraging.